Alicia Morgans: Hi, my name is Alicia Morgans and I am a GU medical oncologist and associate professor of medicine at Northwestern University. I am so pleased to have here with me today, Dr. Bertrand Tombal, who is a urologist in Brussels, Belgium. He is here to talk with us about some of the cardiovascular […]
Michael Cookson: Thank you very much, Dr. Michael Cookson here from the University of Oklahoma. I’m a Professor and Chair at the Stephenson Cancer Center, and I’m also the President of the SUO. I appreciate the opportunity to be with you on this exciting conversation regarding some of the complications of ADT. My first question […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University. I am so thrilled to have here with me today, a friend and colleague, Dr. Matthew Smith, who is a Professor of Medicine at Harvard Medical School and the Director of the GU […]
Alicia Morgans: Hi. My name is Alicia Morgans and I’m a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to start today a round table discussion about cardiovascular health and men with prostate cancer treated with androgen deprivation therapy. I have multiple colleagues here with me today, so let’s […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so thrilled to have here with me today a friend and colleague, Dr. Charles Ryan, who is the Director of Hematology, Oncology, and Transplantation at the University of Minnesota in the Masonic […]
Alicia Morgans: Hi, my name is Alicia Morgans, GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so pleased to introduce today, Dr. Javid Moslehi, who’s a cardio-oncologist at Vanderbilt University and an Associate Professor of Medicine. He’s going to talk with us about cardiovascular risks, as they relate to ADT in […]
Androgen deprivation therapy (ADT) is the backbone of systemic therapy for men with prostate cancer (PC); almost one-half of patients receive treatment during their disease course. However, a range of cognitive and other central nervous system (CNS) changes have been associated with ADT.
To evaluate the safety and efficacy of stereotactic radiotherapy (SRT) in metastatic RCC (mRCC) patients concurrently receiving targeted therapy or immunotherapy. Data on mRCC patients was extracted from a retrospective international multicenter register study (TOaSTT) investigating SRT concurrent (≤30d) to TT/ICI.
Current follow-up strategies for patients with renal cell carcinoma (RCC) after curative surgery rely mainly on risk models and the treatment delivered, regardless of the histological subtype. To determine the impact of RCC histological subtype on recurrence and to examine the incidence, pattern, and timing of recurrences to improve follow-up recommendations.
Testicular germ cell tumors (TGCTs) are malignancies with very high curative potential even in metastatic settings, mainly due to the introduction of cisplatin in the treatment of this disease. However, in a group of patients with cisplatin-refractory disease or with progressive disease despite high-dose salvage chemotherapy treatment, the prognosis is typically dismal.
